Recurrent or Persistent Low-Grade Serous Cancer of the Ovary, Fallopian Tube or Primary Peritoneum

A Study of MEK162, Recurrent or Persistant Low-Grade Serous Chemotherapy of the Ovary, Fallopian Tube or Primary Peritoneum

Objective

Phase 3 randomized,  open-label study will evaluate MEK 162 vs physician choice of selected chemotherapies in patients with low-grade serous carcinoma of the ovaries, fallopian tubes or primary peritneal who have recurrent or persistent disease following:

• at least 1 prior platinum-based chemotherapy
• no more than 3 prior lines of chemotherapy
• Central pathology review of patient histology tumor specimen

IRB Protocol Number

ARRAY-162-311

Principal Investigator(s)

Randall Gibb, MD

Sponsor(s)

Array BioPharma Inc.

Contact

Judy Miller, RN CCRP at 406-435-7482
or jmiller4@billingsclinic.org